Synthesis and biological evaluation of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504), a dual inhibitor of TXA2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species (AOS).
Terao
S
S
Chemistry Research Laboratories, Takeda Chemical Industries, Ltd, Osaka, Japan.
Ohkawa
S
S
Terashita
Z
Z
Shibouta
Y
Y
Nishikawa
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D000975:Antioxidants / Q000138:chemical synthesis / Q000494:pharmacology*; D016227:Benzoquinones / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D005609:Free Radicals; D005921:Glomerulonephritis / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007975:Leukotriene B4 / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D015394:Molecular Structure; D010100:Oxygen / Q000378:metabolism*; D011692:Puromycin Aminonucleoside / Q000633:toxicity; D051381:Rats; D013329:Structure-Activity Relationship; D013929:Thromboxane B2 / Q000096:biosynthesis; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000975:Antioxidants; D016227:Benzoquinones; D005609:Free Radicals; D016859:Lipoxygenase Inhibitors; C067513:CV 6504; D007975:Leukotriene B4; D013929:Thromboxane B2; D011692:Puromycin Aminonucleoside; D015121:6-Ketoprostaglandin F1 alpha; D013930:Thromboxane-A Synthase; D010100:Oxygen